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Previously, we have described the Galanin (GAL) and Neuropeptide Y Y1 (NPYY1) 
interactions through GAL receptor 2  and NPYY1 receptor 1 (GALR2/NPYY1R) 
heterodimers in the Dentate Gyrus (DG) of the Hippocampus, using autoradiographic, 
in situ hybridization and in situ proximity ligation assay(PLA) (1,2). The current work is 
to evaluate GALR2 and NPYY1R interactions in relation to depression-like behaviour 
and c-Fos expression in the Hippocampal DG.  
Rats (n=6-8) were forced to swim for a 15-min period (pre-test) and 24 h later were 
subjected to a 5-min swimming session (test) 15 min after the administration alone or 
in combination of GAL, the NPYY1R agonist [Leu31,Pro34]NPY and the GALR2 
antagonist M871. The total duration of immobility, swimming, and climbing periods 
were scored during the test. For c-Fos immunohistochemistry, experimental groups of 
rats were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and perfused with 
4 % Paraformaldehyde 90 min after icv injections. Then, brains were coronally sliced 
and immunostained. As primary antibodies, an antibody against c-Fos protein 
(1:5000, sc- 52, Santa Cruz Biotechnology, CA, USA), revealed with 3,3´-
Diaminobenzidine (DAB) plus nickel, was used as an indirect marker of neural 
activity. The antibody to Calbindin-D28 k (1:1000, Santa Cruz Biotecnology, CA, 
USA), revealed with DAB, was used to outline the granular region since it marks 
mainly hippocampal granule cells. Sections were analyzed using the optical 
fractionator stereological method. 
We observed that icv injection of GAL and NPYY1R agonist significantly enhanced 
the decrease in the immobility (p<0,001) and the increase in the swimming behaviour 
(p<0,001) compared with the NPYY1R agonist alone. Moreover, a significant 
enhancement of the decrease in climbing behavior (p<0.05) was also observed. 
Furthermore, GALR2 is involved in this GALR/NPYY1R interaction, since the 
presence of the GALR2 antagonist M871 counteracted the enhancement of the 
decrease in immobility (p<0.01) and in climbing behavior (p<0.05) as well as the 
increase in swimming time (p<0.001) induced by the coadministration of GAL and 
NPYY1R agonist in the FST. 
Specific cells populations within DG subregions may be involved in this behavioural 
effect since the coadministration of GAL and NPYY1 agonist enhances the NPYY1R-
mediated reduction (p<0.05) in the number of c-Fos immunoreactive nuclei in the 
polymorphic region. In this region, the GABA interneurons could be involved in the 
interaction since c-Fos IR colocalized with a GABAergic marker (GAD65/67) after 
NPYY1R agonist injection. Moreover, within the granular cells layer, GAL and NPYY1 
agonist coadministration significantly increased c-Fos IR expression in the entire 
granular cell layer compared with GAL (p<0.05) and [Leu31,Pro34]NPY (p<0.01) alone. 
Again, the co-treatment with the GALR2 antagonist M871 completely reversed the 
GAL contribution to the responses in both regions, the polymorphic and the granular 
layer of the DG, demonstrating the involvement of GALR2 in the GAL actions. 
These results indicate that GALR2/NPYY1R interactions can provide a novel 
integrative mechanism in DG in depression-related behavior and may give the basis 
for the development of drugs targeting GALR2/NPYY1R heteroreceptor complexes in 
the DG of the hippocampus for the treatment of depression. Study supported by Junta 
de Andalucia CVI6476 and Proyecto Puente-Universidad de Málaga.  
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